Related Experiment Videos
Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10
João Eduardo Salles1, Valdir A Moisés, Dirceu R Almeida
1Division of Endocrinology, Department of Medicine, Federal University of São Paulo, Rua Botucatu, 740 0434-970 São Paulo, SP, Brazil.
Diabetes Research and Clinical Practice
|October 29, 2005
Summary
Maternally-inherited diabetes and deafness (MIDD) is linked to a mitochondrial gene mutation. Coenzyme Q10 (CoQ10) supplementation improved cardiac function in a patient with MIDD-related heart failure.
Area of Science:
- Genetics
- Cardiology
- Metabolic Disorders
Background:
- Maternally-inherited diabetes and deafness (MIDD) is associated with the mitochondrial tRNA Leu (UUR) gene mutation at position 3243.
- The link between this mutation, diabetes, and cardiomyopathy requires further investigation regarding cardiac involvement and treatment.
Observation:
- A case study of a patient with MIDD presented with congestive heart failure.
- Echocardiography revealed impaired left ventricular function.
Findings:
- Coenzyme Q10 (CoQ10) administration (150 mg/day) led to significant improvements in left ventricular function.
- Fractional shortening (FS) increased from 26% to 34%, and ejection fraction (EF) rose from 49% to 64%.
- Discontinuation of CoQ10 resulted in a decline in systolic function parameters, suggesting a beneficial effect.
Implications:
- Identifying MIDD and associated cardiomyopathy due to mitochondrial gene mutations has therapeutic potential.
- Coenzyme Q10 (CoQ10) shows promise as an adjunctive therapy for cardiac dysfunction in these patients.